Panel Discussion: How RWE & AI Are Actually Shaping Research & Development & Evidence Strategy Today From Methodology to Impact
9:05 am - Thursday 29th October 2026
- How is real‑world evidence being used across the full development and post‑launch lifecycle, and how should organizations integrate RWE earlier while leveraging AI and other methods to enhance decision‑making at each stage?
- How is real‑world evidence being used in practice to inform R&D and lifecycle decisions beyond methodological decisions?
- What does real‑world AI adoption look like beyond pilots, and what has been required to move from experimentation to scalable, trusted impact?
- Where are the real credibility risks when integrating AI and RWE into regulated evidence generation, and how are leading organizations managing them?
- How should companies balance speed, innovation, and scientific defensibility as AI becomes embedded across evidence generation workflows?
- What strategic and governance capabilities will distinguish evidence leaders over the next 3–5 years?
Speakers:
Vice President - Clinical Data Science, Evidence Short-Term Assignment, Global Medical Affairs, Product & Portfolio Strategy
Novo Nordisk
Vice President & Global Head of Evidence Generation & Advanced Analytics
Astellas Pharma
Senior Vice President & Head, Medical Evidence Generation, Managed Access Programs, & Real-World Evidence
Bristol Myers Squibb